Lurtotecan (BioDeep_00000707104)
代谢物信息卡片
Lurtotecan
化学式: C28H30N4O6 (518.2165239999999)
中文名称: 勒托替康
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC6=C(C=C5N=C4C3=C2)OCCO6)CN7CCN(CC7)C)O
InChI: InChI=1S/C28H30N4O6/c1-3-28(35)20-11-22-25-18(14-32(22)26(33)19(20)15-38-27(28)34)17(13-31-6-4-30(2)5-7-31)16-10-23-24(12-21(16)29-25)37-9-8-36-23/h10-12,35H,3-9,13-15H2,1-2H3/t28-/m0/s1
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor
D000970 - Antineoplastic Agents
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- PubChem: 60956
- DrugBank: DB12222
- ChEMBL: CHEMBL305666
- ChEMBL: CHEMBL341028
- CAS: 149882-10-0
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Hsin-I Chang, Ming-Kung Yeh. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy.
International journal of nanomedicine.
2012; 7(?):49-60. doi:
10.2147/ijn.s26766. [PMID: 22275822] - Pius S Fasinu, Patrick J Bouic, Bernd Rosenkranz. An overview of the evidence and mechanisms of herb-drug interactions.
Frontiers in pharmacology.
2012; 3(?):69. doi:
10.3389/fphar.2012.00069. [PMID: 22557968] - Roos L Oostendorp, Evita van de Steeg, Cornelia M M van der Kruijssen, Jos H Beijnen, Kathryn E Kenworthy, Alfred H Schinkel, Jan H M Schellens. Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.
Drug metabolism and disposition: the biological fate of chemicals.
2009 Apr; 37(4):917-23. doi:
10.1124/dmd.108.024901. [PMID: 19139163] - Maria Laura Immordino, Franco Dosio, Luigi Cattel. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential.
International journal of nanomedicine.
2006; 1(3):297-315. doi:
". [PMID: 17717971] - Francis J Giles, Martin S Tallman, Guillermo Garcia-Manero, Jorge E Cortes, Deborah A Thomas, William G Wierda, Srdan Verstovsek, Marta Hamilton, Emma Barrett, Maher Albitar, Hagop M Kantarjian. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
Cancer.
2004 Apr; 100(7):1449-58. doi:
10.1002/cncr.20132. [PMID: 15042679] - M Bayés, X Rabasseda, J R Prous. Gateways to clinical trials.
Methods and findings in experimental and clinical pharmacology.
2003 Jul; 25(6):483-506. doi:
. [PMID: 12949633] - Diederik F S Kehrer, Annelies M Bos, Jaap Verweij, Harry J Groen, Walter J Loos, Alex Sparreboom, Maja J A de Jonge, Marta Hamilton, Terri Cameron, Elisabeth G E de Vries. Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2002 Mar; 20(5):1222-31. doi:
10.1200/jco.2002.20.5.1222. [PMID: 11870164] - Walter J Loos, Jaap Verweij, Diederik F S Kehrer, Peter de Bruijn, Franciscus M H de Groot, Marta Hamilton, Kees Nooter, Gerrit Stoter, Alex Sparreboom. Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2002 Mar; 8(3):856-62. doi:
NULL. [PMID: 11895919] - J H M Schellens, B Heinrich, M Lehnert, M E Gore, S B Kaye, P Dombernowsky, R Paridaens, A T van Oosterom, J Verweij, W J Loos, H Calvert, N Pavlidis, H Cortes-Funes, J Wanders, M Roelvink, C Sessa, K Selinger, P S Wissel, T Gamucci, A R Hanauske. Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
Investigational new drugs.
2002 Feb; 20(1):83-93. doi:
10.1023/a:1014454821885. [PMID: 12003197] - Hulya Ulukan, Peter W Swaan. Camptothecins: a review of their chemotherapeutic potential.
Drugs.
2002; 62(14):2039-57. doi:
10.2165/00003495-200262140-00004. [PMID: 12269849] - J P Desjardins, E A Abbott, D L Emerson, B E Tomkinson, J D Leray, E N Brown, M Hamilton, L Dihel, M Ptaszynski, R A Bendele, F C Richardson. Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice.
Anti-cancer drugs.
2001 Mar; 12(3):235-45. doi:
10.1097/00001813-200103000-00009. [PMID: 11290871] - D L Emerson, R Bendele, E Brown, S Chiang, J P Desjardins, L C Dihel, S C Gill, M Hamilton, J D LeRay, L Moon-McDermott, K Moynihan, F C Richardson, B Tomkinson, M J Luzzio, D Baccanari. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2000 Jul; 6(7):2903-12. doi:
NULL. [PMID: 10914740] - W J Loos, P de Bruijn, J Verweij, A Sparreboom. Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography.
Anti-cancer drugs.
2000 Jun; 11(5):315-24. doi:
10.1097/00001813-200006000-00001. [PMID: 10912947] - W J Loos, D Kehrer, E Brouwer, J Verweij, P de Bruijn, M Hamilton, S Gill, K Nooter, G Stoter, A Sparreboom. Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications.
2000 Jan; 738(1):155-63. doi:
10.1016/s0378-4347(99)00513-7. [PMID: 10778937] - G T Colbern, D J Dykes, C Engbers, R Musterer, A Hiller, E Pegg, R Saville, S Weng, M Luzzio, P Uster, M Amantea, P K Working. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research.
1998 Dec; 4(12):3077-82. doi:
NULL. [PMID: 9865923] - L Paz-Ares, R Kunka, D DeMaria, J Cassidy, M Alden, P Beranek, S Kaye, D Littlefield, D Reilly, S Depee, P Wissel, C Twelves, P O'Dwyer. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
British journal of cancer.
1998 Nov; 78(10):1329-36. doi:
10.1038/bjc.1998.679. [PMID: 9823974] - S G Eckhardt, S D Baker, J R Eckardt, T G Burke, D L Warner, J G Kuhn, G Rodriguez, S Fields, A Thurman, L Smith, M L Rothenberg, L White, P Wissel, R Kunka, S DePee, D Littlefield, H A Burris, D D Von Hoff, E K Rowinsky. Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Clinical cancer research : an official journal of the American Association for Cancer Research.
1998 Mar; 4(3):595-604. doi:
NULL. [PMID: 9533526] - C J Gerrits, J H Schellens, G J Creemers, P Wissel, A S Planting, J F Pritchard, S DePee, M de Boer-Dennert, M Harteveld, J Verweij. The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
British journal of cancer.
1997; 76(7):946-51. doi:
10.1038/bjc.1997.490. [PMID: 9328158] - C J Gerrits, G J Creemers, J H Schellens, P Wissel, A S Planting, R Kunka, K Selinger, M de Boer-Dennert, Y Marijnen, M Harteveld, J Verweij. Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
British journal of cancer.
1996 Mar; 73(6):744-50. doi:
10.1038/bjc.1996.130. [PMID: 8611374] - C G Stafford, R L St Claire. High-performance liquid chromatographic analysis of the lactone and carboxylate forms of a topoisomerase I inhibitor (the antitumor drug GI147211) in plasma.
Journal of chromatography. B, Biomedical applications.
1995 Jan; 663(1):119-26. doi:
10.1016/0378-4347(94)00430-d. [PMID: 7704198]